Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HSPB1 | P04792 | 7/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27637132 | 0.92 | MAPT (0.50) | MAPTPIN1SMN1; SMN2HSPB1PARP10 | |
| SCHEMBL4464871 | 0.89 | EGLN1 (0.41) | MAPTPIN1SMN1; SMN2HSPB1ALDH1A1 | |
| SCHEMBL29569131 | 0.86 | HSPB1 (0.63) | MAPTHSPB1ALDH1A1GAALMNA | |
| SCHEMBL4471402 | 0.86 | HSPB1 (0.49) | MAPTPIN1HSPB1ALDH1A1GAA | |
| SCHEMBL21384004 | 0.82 | HPGD (0.53) | MAPTPIN1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL4460183 | 0.81 | HSPB1 (0.59) | MAPTHSPB1ALDH1A1GAAMEN1 | |
| SCHEMBL27617961 | 0.81 | HSPB1 (0.59) | MAPTHSPB1ALDH1A1GAAMEN1 | |
| SCHEMBL6451636 | 0.81 | HSPB1 (0.40) | MAPTHSPB1ALDH1A1GAALMNA | |
| SCHEMBL2659166 | 0.80 | PIN1 (0.47) | MAPTPIN1ALDH1A1LMNAHTT | |
| SCHEMBL29806360 | 0.80 | PIN1 (0.47) | MAPTPIN1ALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517992-B2 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2009-04-14 | — | — | US | disclosed |
| US-7517992-B2 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2009-04-14 | — | — | US | disclosed |
| US-7517992-B2 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2009-04-14 | — | — | US | disclosed |
| EP-1534276-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2006-07-27 | — | — | US | disclosed |
| CN-1694700-A | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2005-11-09 | — | — | CN | disclosed |
| EP-1534276-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004021969-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR2H, POLR2E, POLR1E | MAPT 4367/4885PIN1 3328/4885SMN1; SMN2 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.